Summary & Overview
HCPCS J7309: Methyl Aminolevulinate Topical 16.8% 1g
Headline: HCPCS Level II code J7309 covers methyl aminolevulinate topical formulation used in photodynamic dermatologic therapy.
Lead: HCPCS Level II code J7309 designates methyl aminolevulinate (MAL) topical 16.8%, 1 gram, a photosensitizing agent applied in dermatologic procedures to treat superficial skin lesions. The code captures the drug product component of photodynamic therapy and is relevant for billing outpatient dermatology services and ambulatory procedures nationwide.
Why it matters: Accurate coding of J7309 ensures appropriate capture of the pharmacologic component of photodynamic procedures and supports consistent payment and utilization tracking across payers. This has implications for provider reimbursement workflows and outpatient dermatology practice operations.
Payers covered: The analysis considers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: Readers will find a concise description of the clinical use and service context for J7309, payer landscape and common modifiers used with HCPCS drug codes, benchmarking considerations where available, and notes on typical sites of service. Data limitations are noted where input fields were not provided. This summary provides a national, payer-agnostic overview useful for billing, coding, and administrative staff supporting dermatologic photodynamic therapy services.
Billing Code Overview
HCPCS Level II code J7309 describes methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 gram. The product is a topical photodynamic therapy agent used in dermatologic procedures to treat certain superficial skin lesions. Service type: topical dermatologic pharmacologic agent. Typical site of service: outpatient dermatology clinics, ambulatory surgical centers, and physician offices.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient presents to a dermatology clinic for treatment of actinic keratoses and superficial non-melanoma skin cancers on the face and scalp. The clinician diagnoses multiple field lesions on contiguous areas that are suitable for photodynamic therapy (PDT) using topical methyl aminolevulinate (J7309). The clinical workflow: the provider documents diagnosis and obtains consent; the treatment area is cleansed and prepped; Methyl aminolevulinate (MAL) 16.8% 1 g is applied topically to cover the lesions and an appropriate surrounding margin; the medication is occluded per manufacturer instructions for the incubation period (typically 30–60 minutes); after incubation the area is illuminated with a specified light source to activate the photosensitizer; post-procedure wound care and analgesia are advised; follow-up is scheduled to assess response and manage adverse effects. Typical site of service is an outpatient dermatology clinic, ambulatory surgical center, or physician office equipped for PDT. The typical patient scenario involves adult or elderly patients with multiple actinic keratoses, Bowen disease (squamous cell carcinoma in situ), or superficial basal cell carcinoma where topical PDT is clinically appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |